Literature DB >> 8110296

Optimum use of a spacer device.

P W Barry1, C F Robertson, C O'Callaghan.   

Abstract

Nedocromil sodium given by the Fisonair spacer should be inhaled immediately. Multiple actuations into the spacer should be avoided. Delay of 20 seconds before sampling reduced the amount of drug available for inhalation in the respirable range by 81%. Placing two actuations into the spacer reduced the amount of drug available by 47%.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8110296      PMCID: PMC1029658          DOI: 10.1136/adc.69.6.693

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  6 in total

1.  Large volume plastic spacers in asthma.

Authors:  D Keeley
Journal:  BMJ       Date:  1992-09-12

2.  Drug delivery from holding chambers with attached facemask.

Authors:  M L Everard; A R Clark; A D Milner
Journal:  Arch Dis Child       Date:  1992-05       Impact factor: 3.791

3.  The use of reservoir devices for the simultaneous delivery of two metered-dose aerosols.

Authors:  A R Clark; G Rachelefsky; P L Mason; M J Goldenhersh; A Hollingworth
Journal:  J Allergy Clin Immunol       Date:  1990-01       Impact factor: 10.793

4.  Improvement in sodium cromoglycate delivery from a spacer device by use of an antistatic lining, immediate inhalation, and avoiding multiple actuations of drug.

Authors:  C O'Callaghan; J Lynch; M Cant; C Robertson
Journal:  Thorax       Date:  1993-06       Impact factor: 9.139

5.  Improvement of pressurised aerosol deposition with Nebuhaler spacer device.

Authors:  S P Newman; A B Millar; T R Lennard-Jones; F Morén; S W Clarke
Journal:  Thorax       Date:  1984-12       Impact factor: 9.139

6.  Double blind, placebo controlled study of nedocromil sodium in asthma.

Authors:  L Armenio; G Baldini; M Bardare; A Boner; R Burgio; G Cavagni; M La Rosa; F Marcucci; M Miraglia del Giudice; M R Pulejo
Journal:  Arch Dis Child       Date:  1993-02       Impact factor: 3.791

  6 in total
  9 in total

Review 1.  The economic aspects of drug delivery in asthma.

Authors:  R J Massie; C M Mellis
Journal:  Pharmacoeconomics       Date:  1997-05       Impact factor: 4.981

Review 2.  Nebuliser therapy in childhood.

Authors:  P W Barry; C O'Callaghan
Journal:  Thorax       Date:  1997-04       Impact factor: 9.139

3.  Early use of inhaled nedocromil sodium in children following an acute episode of asthma.

Authors:  A M Edwards; J Lyons; E Weinberg; F Weinberg; J D Gillies; G Reid; C F Robertson; P Robinson; M Dalton; P Van Asperen; C Wilson; J Mullineux; A Mullineux; P D Sly; M Cox; A F Isles
Journal:  Thorax       Date:  1999-04       Impact factor: 9.139

4.  The effect of delay, multiple actuations and spacer static charge on the in vitro delivery of budesonide from the Nebuhaler.

Authors:  P W Barry; C O'Callaghan
Journal:  Br J Clin Pharmacol       Date:  1995-07       Impact factor: 4.335

5.  A comparative analysis of the particle size output of beclomethasone diproprionate, salmeterol xinafoate and fluticasone propionate metered dose inhalers used with the Babyhaler, Volumatic and Aerochamber spacer devices.

Authors:  P W Barry; C O'callaghan
Journal:  Br J Clin Pharmacol       Date:  1999-04       Impact factor: 4.335

6.  Inhalational drug delivery from seven different spacer devices.

Authors:  P W Barry; C O'Callaghan
Journal:  Thorax       Date:  1996-08       Impact factor: 9.139

Review 7.  Use of inhaler devices in pediatric asthma.

Authors:  Fernando Maria De Benedictis; David Selvaggio
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

8.  The challenge of delivering therapeutic aerosols to asthma patients.

Authors:  Federico Lavorini
Journal:  ISRN Allergy       Date:  2013-08-05

9.  Usefulness of Nonvalved Spacers for Administration of Inhaled Steroids in Young Children with Recurrent Wheezing and Risk Factors for Asthma.

Authors:  Carlos Kofman; Alejandro Teper
Journal:  Can Respir J       Date:  2018-09-03       Impact factor: 2.409

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.